Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes.
Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
PMID: 34694878
2022
Antimicrobial agents and chemotherapy
Table: D67D/N
Table: D67N
Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria.
PMID: 34741609
2022
The Journal of antimicrobial chemotherapy
Result: Sixteen participants had all of the TAM 1 pathway mutations (M41L, L210W and T215Y), 11 had all of the TAM 2 pathway mutations (D67N, K70R, T215F and K219Q/E) and four had the mutations for both pathways.
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
PMID: 34694877
2022
Antimicrobial agents and chemotherapy
Result: The treatment-emergent NRTI resistance-associated substitution D67N was observed in 1 participant.
Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China.
Abstract: Of 925 patients with VL >= 1000 copies/mL, 495 (53.5%) acquired HIVDR, the most common DRAM were K103N 43.8%, M184I/V 43.2%, M41L 19.0%, D67N/G 16.4%, V181C/I/V 14.5%, G190A/S 13.9% and K101E 13.7% (multidrug resistance: 75.8%), and patients with HIVDR had a higher risk of CD4 cell counts < 200 cells/muL (AOR 5.8, 95% CI 4.6-7.4, p < 0.01) comparing with those without HIVDR.
Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania.
PMID: 35107140
2022
The Journal of antimicrobial chemotherapy
Abstract: Common mutations in RT were M184V (75%), T215Y (41.1%), K103N (39.3%), M41L (32.1%), D67DN (30.3%), G190A (28.6%) and A98G (26.8%).
Discussion: The most plausible explanations for the occurrence of T215Y, D67N, M41L, K219K/Q and K70R TAMs among patients with tenofovir disoproxil fumarate-based ART regimen failure are that these TAMs were transmitted drug resistance RAMs (TDR-RAMs) or were selected by exposure to undisclosed thymidine analogue-based regimens.
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
PMID: 34897227
2022
Journal of acquired immune deficiency syndromes (1999)
Table: D67N
Increase in HIV-1-transmitted drug resistance among ART-naive youths at the China-Myanmar border during 2009 ~ 2017.
Result: K65R/E/N and K70E mutations conferred resistance to TDF and M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E conferred resistance to AZT.
Result: M184 V/I 87 (28.8%), K65R/E/N 27 (8.9%), L74 V 3 (1.0%), and Y115F 12 (4.0%) were the mutations conferring resistance to NRTIs, along with thymidine analog mutations (TAMs) M41L 14 (4.6%), D67N 17 (5.6%), K70R 20 (6.6%), L210W
Correlation of HIV-1 drug resistant mutations and virologic failure.
PMID: 34584606
2021
The Pan African medical journal
Introduction: These mutations included M184V, K65R,D67N,K70R,K219Q,Q151M, T215F, M41L, T69N, V75M, M41L, T69N, V75M, D67G, V75M, M184I, T215N, M41LM, T215N, K219N,210W, T215Y as NRTIs
HIV mutation literature information.
PMID: 
2022
AIDS (London, England)
Browser Board
Co-occurred Entities
Filtrator
ViMRT